Sentences with phrase «immunogenicity data»

Not exact matches

White MT, Verity R, Griffin JT, et al.White MT, Verity R, Griffin JT, Asante KP, Owusu - Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, Adjei S, Agbenyega T, Ogutu B, Otieno L, Otieno W, Agnandji ST, Lell B, Kremsner P, Hoffman I, Martinson F, Kamthunzu P, Tinto H, Valea I, Sorgho H, Oneko M, Otieno K, Hamel MJ, Salim N, Mtoro A, Abdulla S, Aide P, Sacarlal J, Aponte JJ, Njuguna P, Marsh K, Bejon P, Riley EM, Ghani AC close, 2015, Immunogenicity of the RTS, S / AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial, Lancet Infectious Diseases, Vol: 15, ISSN: 1473 - 3099, Pages: 1450 - 1458

Researchers seek to sustain or increase this effect, and these clinical trials will enable them to collect more data and samples for immunogenicity studies.

CAMBRIDGE, Mass., April 27, 2017 — Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) Therapeutics ™ to create a new generation of transformative medicines for patients, today announced positive interim data from an ongoing Phase 1 study of mRNA - 1440, an mRNA infectious disease vaccine against avian H10N8 influenza, demonstrating mRNA - 1440 induced high levels of immunogenicity, and was safe and well tolerated.

In April 2017, Moderna published human data for its mRNA vaccine technology in Molecular Therapy, which showed that its first prophylactic vaccine candidate, mRNA - 1440 — an mRNA prophylactic vaccine against avian H10N8 influenza — induced high levels of immunogenicity and was safe and well tolerated.

Safety and immunogenicity analyses were based on intention - to - treat, such that all available data were included in analyses.

All available data from all participants, including partial data from participants lost to follow - up, were included in both safety and immunogenicity analyses.

Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA - 1440, Induces High Levels of Immunogenicity

WRAIR and collaborators will share data related to assays designed to measure antibody responses following vaccination with ZPIV, biologic samples generated during the performance of animal studies, and biologic samples generated during the performance of early human trials assessing the safety and immunogenicity of ZPIV.

Glenda Gray, executive director of the Wits Health Consortium's perinatal HIV research unit in South Africa, presented data today at the HIV R4P conference in Cape Town indicating that the prime - boost vaccine candidates initially tested in the RV144 trial in Thailand — the only HIV vaccine trial to date to show any efficacy — induced cross-clade immune responses in a Phase I safety trial conducted in South Africa, with immunogenicity similar to or greater than that of the responses induced in Thai volunteers.